Composition for use in the prophylaxis of allergic disease

A technology for allergic diseases and compositions, which can be used in allergic diseases, sensory diseases, drug combinations, etc., and can solve problems such as expensive and side effects

Pending Publication Date: 2019-01-04
SOC DES PROD NESTLE SA
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Widely used therapies often only provide symptomatic relief (eg, antihistamines, decongestants, and steroids), and such treatments may have drawbacks, such as side effects such as drowsin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for use in the prophylaxis of allergic disease
  • Composition for use in the prophylaxis of allergic disease
  • Composition for use in the prophylaxis of allergic disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Materials and methods

[0088] Soybean Oil - Obtained from Florin AG, Switzerland (Florin AG, Switzerland; Lot No. 280813). The fatty acids of the oil are mainly composed of saturated fatty acids palmitic acid (14%) and stearic acid (4%), n-6PUFA LA (47%) and GLA (0.2%), oleic acid (27%) and n-3PUFA ALA (5 %)composition. DGLA, EPA and DHA were undetectable.

[0089] High DHA fish oil (containing 20-26% docosahexaenoic acid (DHA; 22:6n3) and 7% eicosapentaenoic acid (EPA; 20:5n3) was obtained from Sofinol SA (Nestlé corporation ) subsidiary). Other major fatty acids consist of palmitic acid (21%), palmitoleic acid (3%), stearic acid (5%) and oleic acid (19%). GLA and DGLA levels are below 0.2%, The ARA content is about 1%.

[0090] DGLA oil is derived from the fungus Mortierella alpina from Nippon Suisan Kaisha Ltd. The DGLA content is 35.6%. Other major fatty acids consist of palmitic acid (16.3%), stearic acid (7.1%), oleic acid (8.2%), LA (6.4%), GLA (2.6%), b...

Embodiment 2

[0103] Materials and methods

[0104] RBL-2H3 cells; rat basophilic leukemia cells were cultured under standard conditions in a culture medium containing 15% serum. Once a sufficient number of cells were present in the dish, the sodium salts of the various fatty acids were added directly to the medium and the cells were incubated with these fatty acids for 24 hours. Cells also received phorbol 12-myristate 13-acetic acid ("PMA"; final concentration 50 ng / mL) and ionomycin ("IM"; final concentration 0.125 μΜ) during the last 18 hours of this incubation period , to stimulate cells to secrete IL4.

[0105] result

[0106] Figure 5 It is shown that cells incubated with DGLA (final concentration 60 μΜ) produced less IL4 after stimulation with PMA and IM than cells not treated with additional fatty acids (control). The same was observed for cells incubated with 2.14 μM of a fatty acid mixture ("NIF") consisting of DHA and EPA mixed in a 3:1 ratio. A synergistic decrease in...

Embodiment 3

[0108] Pregnant mice were divided into 2 groups and fed a low-fat based diet (standard rodent diet) from gestation day 5 until weaning of the pups, in which diet was added (per 95 g of the diet): 5 g soybean oil ( control group) or 2.5g fish oil+2.5g DGLA oil (fish oil+DGLA group). The oil composition is described in Example 1.

[0109] From the second week of life, the pups were able to chew the food in the cage, so to avoid direct exposure of the pups to the diet, the mother and her pups were fed a control diet, but the mother was given an additional daily via gavage: 0.1ml Soybean oil or 0.05ml high DHA fish oil + 0.05ml DGLA oil. Therefore, the pups never had direct access to the diet.

[0110] After weaning, all pups received a control diet. Two weeks after weaning, pups (10 pups per group) received skin patches as described in Example 1. On the last day of skin assessment, mice were humanely sacrificed and skin-draining brachial lymph nodes were collected.

[0111] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a dihomo-gamma-linolenic acid (DGLA) or a composition comprising DGLA for use in the prophylaxis of allergic disease in the offspring of mammalian subject, wherein said DGLA isadministered to said subject pre-pregnancy and/or during pregnancy and/or during lactation.

Description

technical field [0001] The present invention relates to compositions for the prevention of allergies and allergic diseases. In particular, the present invention relates to dihomo-gamma-linolenic acid (dihomo-gamma-linolenic acid) (hereinafter referred to as DGLA) or dihomo-gamma-linolenic acid containing Compositions for preventing allergies and allergic diseases in offspring of an individual. Background technique [0002] Allergies and allergic diseases can best be described as the hypersensitivity of the body, and in particular the immune system, to foreign substances, which are usually benign. Over the past decades, an increasing number of children and adults suffer from allergies and allergic diseases such as eczema, atopic dermatitis, allergic rhinitis and asthma; these increasing The health care system poses a huge burden. [0003] Despite extensive research, treatment options for patients with allergies or allergic diseases are limited. Widely used therapies often...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/202A61P27/14
CPCA61K31/202A61P27/14A61P37/08A61K2300/00
Inventor E·埃克哈特C·南布里尼L·茹尔丹
Owner SOC DES PROD NESTLE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap